Cd22 antibodies and methods of using the same
AssigneeMemorial Sloan Kettering Cancer Center
InventorsNai-Kong V. CHEUNG, Sayed Shahabuddin HOSEINI, Mahiuddin AHMED
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD22 protein. The antibodies of the present technology are useful in methods for detecting and treating a CD22-associated cancer, a CD22-associated autoimmune disease, or a CD22-associated allergy in a subject in need thereof.
Claims58
An antibody or antigen binding fragment thereof comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein:
- (a) the VH comprises an amino acid sequence selected from the group consisting of:
- SEQ ID NOs:
- 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16;
- and
- (b) the VL comprises an amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 21, and SEQ ID NO:
- 22, optionally wherein
- the antibody or antigen binding fragment binds to a CD22 polypeptide comprising an Ig-like C2-type 1 domain and/or an Ig-like C2-type 2 domain, or
- the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a bispecific antibody, or the antigen binding fragment is selected from the group consisting of Fab, F(ab′)2, Fab′, scFv, and Fv, or
- wherein the bispecific antibody binds to T cells, B-cells, myeloid cells, plasma cells, or mast-cells, or wherein the bispecific antibody or antigen binding fragment binds to CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCR gamma/delta, NKp46, KIR, or a small molecule DOTA hapten, or
- wherein the bispecific antibody or antigen binding fragment comprises an amino acid sequence selected from any one of SEQ ID NOs:
- 47-82.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An antibody comprising a heavy chain (HC) amino acid sequence comprising SEQ ID NO:
- 25, SEQ ID NO:
- 29, SEQ ID NO:
- 33, SEQ ID NO:
- 36, SEQ ID NO:
- 38, SEQ ID NO:
- 40, SEQ ID NO:
- 42, SEQ ID NO:
- 44, SEQ ID NO:
- 46, or a variant thereof having one or more conservative amino acid substitutions, and a light chain (LC) amino acid sequence comprising SEQ ID NO:
- 23, SEQ ID NO:
- 27, SEQ ID NO:
- 31, SEQ ID NO:
- 35, SEQ ID NO:
- 37, SEQ ID NO:
- 39, SEQ ID NO:
- 41, SEQ ID NO:
- 43, SEQ ID NO:
- 45, or a variant thereof having one or more conservative amino acid substitutions, optionally wherein
- the antibody binds to a CD22 polypeptide comprising an Ig-like C2-type 1 domain and/or an Ig-like C2-type 2 domain, or
- the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, or a bispecific antibody,
- and optionally wherein the bispecific antibody binds to T cells, B-cells, myeloid cells, plasma cells, or mast-cells, or wherein the bispecific antibody binds to CD3, CD4, CD8, CD20, CD19, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCR gamma/delta, NKp46, KIR, or a small molecule DOTA hapten.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.